DTE
49
16
BF.B
35
2
AAP
26
5
USB
50
3
STT
48
4
JBHT
46
4
SHW
42
5
WMT
68
-2
BAC
38
3
IVZ
42
13
EW
55
5
VFC
56
6
RCL
74
5
XRX
48
2
ZTS
38
4
AXP
63
3
UNH
42
6
ACN
54
2
NRG
32
5
MCD
52
3
DTE
49
16
BF.B
35
2
AAP
26
5
USB
50
3
STT
48
4
JBHT
46
4
SHW
42
5
WMT
68
-2
BAC
38
3
IVZ
42
13
EW
55
5
VFC
56
6
RCL
74
5
XRX
48
2
ZTS
38
4
AXP
63
3
UNH
42
6
ACN
54
2
NRG
32
5
MCD
52
3
Financhill
Back

Innate Pharma SA 10K Form

Sell
46

IPHA
Innate Pharma SA

Last Price:
$2.06
Seasonality Move:
0.12%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive IPHA News And Ratings

See the #1 stock for the next 7 days that we like better than IPHA

IPHA Financial Statistics

Sales & Book Value

Annual Sales: $56.2M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $0.38
Price / Book: 5.35

Profitability

EPS (TTM): -0.45230
Net Income (TTM): $-36.7M
Gross Margin: $61.4M
Return on Equity: -72.79%
Return on Assets: -18.89%

Innate Pharma SA Earnings Forecast

Key Innate Pharma SA Financial Ratios

  • The Gross Profit Margin over the past 16 years for IPHA is 95.79%.
  • The Selling, General & Administrative Expenses for IPHA have been equal to 22.64% of Gross Profit Margin.
  • The Research & Development expenses have been 107.94% of Revenue.
  • The Interest Expense is -8.45% of Operating Income.
  • The Net Earning history of IPHA is -14.59% of Total Revenues.
  • Per Share Earnings over the last 19 years have been positive in 11 years.

Innate Pharma SA Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: IPHA
Website: innate-pharma.com

Debt

Debt-to-Equity Ratio: 1.23
Current Ratio: 2.92
Quick Ratio: 2.76

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

IPHA Technical Analysis vs Fundamental Analysis

Sell
46
Innate Pharma SA (IPHA) is a Sell

Is Innate Pharma SA a Buy or a Sell?

  • Innate Pharma SA stock is rated a Sell
    The current Innate Pharma SA [IPHA] share price is $2.04. The Score for IPHA is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.